Sign In
1 Mar 2022 07:00
MaxCyte, Inc.
("MaxCyte" or the "Company")
Block Listing Return
Gaithersburg, Maryland - 1 March 2022: MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a leading provider of enabling platform technologies for ex-vivo cell engineering, makes the following notification pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies, regarding its existing block listings:
Name of applicant: | MaxCyte, Inc. | |||
Name of scheme: | MaxCyte Long Term Incentive Plan | |||
Period of return: | From: | 1 September 2021 | To: | 28 February 2022 |
Balance of unallotted securities under scheme(s) from previous return: | 78,658 ordinary shares of common stock of $0.01 each | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 13,000,000 ordinary shares of common stock of $0.01 each | |||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 901,574 ordinary shares of common stock of $0.01 each | |||
Name of contact: | Amanda Murphy, Chief Financial Officer Ron Holtz, Chief Accounting Officer |
Telephone number of contact: | +1 301 944 1660 |
| For further information, please contact:
MaxCyte Contacts: US IR Adviser Gilmartin Group David Deuchler, CFA
|
+1 415-937-5400 ir@maxcyte.com
|
|
| Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden |
+44 (0)20 7886 2500 |
|
|
UK IR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh |
+44 (0)203 709 5700 maxcyte@consilium-comms.com
|
|
|
| ||
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™ GTx™and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.
Follow the stocks
